Cadoret-Manier was most recently chief commercial officer at Grail, a Menlo Park, CA-based startup spun out from Illumina (NASDAQ: ILMN) that is working to develop tests to detect cancer at its earliest stages. She was previously vice president of Genentech’s respiratory business. Prior experience includes roles at Pfizer (NYSE: PFE) and Amylin Pharmaceuticals, since acquired by Bristol-Myers Squibb (NYSE: BMY).
Carlsbad, CA-based Ionis, a developer of RNA-targeted therapeutics, is in the midst of a leadership transition. Founder and CEO Stanley Crooke made a planned transition this month from the top role to that of executive chairman. He was succeeded by Brett Monia, also a founder, who previously served as chief operating officer.